Serva Energy was featured recently in a new podcast from Drug Discovery News  (DDN) highlighting the history of Actinium-225 and its potential as a promising cancer treatment. Stephanie DeMarco, PhD, the host of DDN Dialogues, takes listeners on a journey deep into the core of what makes Actinium-225 the Goldilocks of radioisotopes when it comes to killing cancer cells and why Serva is poised to significantly scale production of this exceedingly rare and valuable isotope. DDN

Serva Energy’s collaboration with the University of California—Irvine Nuclear Reactor Facility was highlighted in a recent news story (March 25, 2024 ) about how the facility is helping usher in a new generation of nuclear scientists. Having famously helped analyze the bullets that killed President John F. Kennedy, the UCI facility, with the support of UCI Assistant Professor Sarah Finkeldei, is collaborating with nuclear innovators, such as Serva, on promising solutions and

NEWS RELEASE November 1, 2023 Serva Energy’s sample measurement of the rare, cancer-killing medical isotope Actinium-225 has been validated by the Massachusetts Institute of Technology (MIT) Nuclear Research Laboratory. It’s the latest milestone in Serva’s development of commercial quantities of Actinium-225 (Ac-225) needed for next-generation Targeted Alpha Therapies. “Some of the best scientists in the world have demonstrated the power of our technology,” said Ian Horva

Nuclear innovation was the focus of a Nuclear Science Week national expo event, Saturday, Oct. 14, with the University of California—Irvine. Members of the Serva team came together with more than 1,200 people—students, educators, and community members—for a day of learning and fun around nuclear science and innovation. “It’s always great talking with kids and members of the community about all the awesome things happening right now in nuclear,” said Ian Horvath, founder and C

Partnership aims to ‘revolutionize’ isotope production in Canada Serva Energy has partnered with the Canadian Nuclear Isotope Council (CNIC), an essential advocate for the world’s supply of a diverse portfolio of isotopes. As the newest member of the CNIC, Serva seeks to engage with the growing Canadian isotope market—leveraging and developing new technologies and providing the tools necessary to produce needed isotopes for novel cancer treatments. “We are excited about this

NEWS RELEASE June 22, 2023 Tempe, AZ — Serva Energy , a nuclear innovation company, has developed a new production method to ramp up the supply of Actinium-225, a cancer-killing isotope in ultra-high demand by oncology researchers and pharmaceutical companies developing Targeted Alpha Therapies (TAT)—a promising step forward in the fight against cancer. The milestone marks the first time a commercial entity has employed a conventional nuclear reactor to produce the life-

This week we are headed to the University of Maryland in College Park, Maryland, for the TRTR and IGORR Research Reactor Conference . Dr. Sarah Jones , Vice President of Serva Medical, will speak as part of a panel discussion on industry collaborations. She will present on Serva’s reactor-based method for producing Actinium-225 (Ac-225) and Serva's ability to scale rapidly through strategic partnerships. “I’m really looking forward to engaging with this panel and connecting

U.S. support for nuclear power has reached the highest level in a decade, according to a new Gallup survey released last month. Fifty-five percent of American adults now support the use of nuclear power—“that’s up four percentage points from last year and reflects the highest level of public support for nuclear energy use in electricity since 2012,” writes Akielly Hu , a news and politics fellow with Grist. With growing bipartisan support and advances in nuclear technologies

Recent investments in nuclear infrastructure focus on the growing demand for medical isotopes, including Actinium-225, the focus of our April newsletter. For those unfamiliar, Actinium-225 is a rare alpha-emitting radionuclide in ultra-high demand for research and development of next-generation precision cancer treatments. "Actinium-225 is the miracle drug we've been wishing for," writes Serva CEO Ian Horvath. "Actinium-225 is a radioisotope that emits alpha particles that de

At Serva Energy, we all know that nuclear power is one of the safest, cleanest forms of energy, but most people might not feel that way. Meet Isabelle Boemeke, creator of the social media persona "Isodope," who is working to spread new, positive memes about nuclear energy as "the world's first nuclear energy influencer." Educating people about our greatest clean energy source, Boemeke debunks decades-old myths about nuclear energy, as well as current objections, through her u

PRESS RELEASE November 14, 2022 "Challenge Accepted" is the fitting theme of the 2022 American Nuclear Society (ANS) Winter Meeting and Technology Expo , to take place November 13-17, at the Arizona Grand Resort, in Phoenix, Ariz., where Serva Energy will be among dozens of companies and organizations exhibiting the latest in nuclear technology solutions. Ian Horvath , CEO and founder of Serva Energy, will be presenting at 1 p.m., on Tuesday, November 15, at the Sensor and

“American competitiveness in science and innovation relies, to a great extent, on the development and production of key isotopes, and Serva is proud to support this mission,” said Ian Horvath , Serva’s founder and CEO, in response to the recent U.S. investment in isotope production and research. Last month, U.S. Secretary of Energy Jennifer M. Granholm spoke at a groundbreaking ceremony for the U.S. Stable Isotope Production and Research Center—a new facility aimed at bolste

Check out our latest newsletter to find out what we've been up to! Interested in subscribing? Join our mailing list !

PRESS RELEASE October 7, 2022 Serva Energy has been selected as a semi-finalist by the Arizona Commerce Authority for the 2022 Arizona Innovation Challenge . Designed to advance opportunities in Arizona for innovation and technology commercialization, the Arizona Innovation Challenge helps early-stage ventures scale. As one of 30 companies selected as a semi-finalist, Serva Energy will advance to the next round of competition. “Choosing 30 semifinalists from over 80 exciting

PRESS RELEASE September 27, 2022 “This is an exciting time for the biomedical research community and nuclear medicine, in particular,” said Dr. Sarah Jones, Vice President of Serva Medical, at Arizona Bioscience Week, where she will be highlighting the significant health care innovations underway at Serva Energy, as part of the White Hat Life Science Investor Conference , September 28-29. “At Serva, we feel we are part of a sea change in nuclear medicine.” Serva Energy is

The threat of climate change and the unreliability of electrical grids, in addition to growing fears about national security, are steering a sea change in the minds of environmentalists, many of whom now view nuclear power as a boon to society in tackling multiple crises. Uri Berliner of National Public Radio reports on the remarkable turnarounds worldwide where resistance to nuclear power is beginning to ebb: "In California , the state's last remaining power plant — Diablo

Serva Energy is one of 32 biotechnology and medical technology companies selected to participate in the White Hat Life Science Investor Conference , September 28-29, during Arizona Bioscience Week. Hosted by AZ Bio, the conference showcases exciting startups and companies from across the Rocky Mountain and Southwest Region. Its aim is to connect investors with a new generation of biotech and healthcare innovators. “We are thrilled to be part of the White Hat and to be among s

“Nuclear energy is at an inflection point,” writes Catherine Clifford in an August 3 article for CNBC , due to promising new technology and the urgent call to fight climate change. “Nuclear energy is getting a second shot at becoming a prominent part of the global energy grid.” Clifford reports that demand for advanced nuclear reactors will be worth $1 trillion globally, according to U.S. Secretary of Energy Jennifer Granholm. Serva CEO Ian Horvath says that estimate is low.

The nuclear innovation company TerraPower, co-founded by Bill Gates, announced $750 million in new funding this week to develop nuclear energy technology and innovations in nuclear medicine. “This is great news and goes to show the tremendous amount of interest in nuclear as a major part of a green energy future,” said Ian Horvath , founder and CEO of Serva Energy. “TerraPower has been working for over a decade on new nuclear technologies. With this infusion, they will move

Get the latest news from Serva Energy by subscribing to our bimonthly newsletter — it's free and gets delivered to your inbox every other month. The August 2022 edition includes updates from our CEO Ian Horvath and our COO Greg Anderson in addition to a look ahead at new projects and the national conferences we will be presenting at, not to mention a roundup of articles we've posted to our blog. Don't miss out — sign up today !